Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Luspatercept versus epoetin alfa in ESA-naive transfusion-dependent lower-risk MDS
NL-OMON60379Phase 3Completed
- Sponsor
- Celgene Corporation
- Start
- Apr 2019
- Modality
- Recombinant Proteins and Enzymes, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in myelodysplastic syndrome (MDS) comparing Luspatercept with Epoetin alfa (2 arms). Primary endpoint: Red blood cell transfusion independence with hemoglobin increase. Started Apr 2019; status: completed.
02
Drugs
luspaterceptepoetin alfa
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NL-OMON60379.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60379.